

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**维亚生物科技控股集团**  
**VIVA BIOTECH HOLDINGS**

*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

## **MAJOR TRANSACTION**

### **DEEMED DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY**

#### **EQUITY TRANSFER AND CAPITAL INJECTION**

The Board is pleased to announce that on June 10, 2023, the Company (together with certain subsidiaries) and Mr. Mao entered into the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents with the Investors, pursuant to which the Investors has conditionally agreed to (i) inject approximately RMB547.72 million (equivalent to approximately US\$77.34 million) in aggregate into VIVA Shanghai; and (ii) acquire approximately US\$7.74 million of the registered capital of VIVA Shanghai from Viva Investment for a consideration of approximately RMB514.60 million (equivalent to approximately US\$72.66 million) in aggregate. The total consideration of the Equity Investment amounted to approximately RMB1,062.32 million.

The net proceeds from the Equity Investment are expected to be approximately RMB1,058.33 million. The Company intends to apply such proceeds to redeem the December 2025 Convertible Bonds on December 30, 2023 (at the option of the bondholders) at 103.08% of its principal amount, together with interest accrued but unpaid.

#### **LISTING RULES IMPLICATIONS**

VIVA Shanghai is an indirect wholly-owned subsidiary of the Company as at the date of this announcement. It is contemplated that the percentage of the Group's shareholding interest in VIVA Shanghai will reduce to 75.79% following the completion of the Equity Investment by the Investors. The Equity Investment, if materialized, may constitute a deemed disposal by the Company under Rule 14.29 of the Listing Rules.

Since one of the applicable percentage ratios (as defined under the Listing Rules) in respect of the Equity Investment and the transactions contemplated thereunder (taking into account the Repurchase Obligations of VIVA Shanghai and Viva Biotech) exceeds 25% but all are less than 75%, the Equity Investment constitutes a major transaction of the Company under Chapter 14 of the Listing Rules, and is subject to the reporting, announcement, circular and shareholders' approval requirements under the Listing Rules. As the Repurchase Obligations is not at the Company's discretion, such right of the Investors is treated as if it had been exercised upon the execution of the Equity Transfer and Capital Injection Agreement and the Shareholders Agreement under Rule 14.74 of the Listing Rules.

#### **DISPATCH OF CIRCULAR**

The Company will convene a general meeting for the purpose of, among other things, considering, and if thought fit, approving the entering into of the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents and the Equity Investment as contemplated thereunder. Pursuant to Rule 14.41(a) of the Listing Rules, a circular containing, inter alia, (i) further details of the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents; (ii) financial information of the Company; and (iii) other information as required by the Listing Rules, together with the notice of the general meeting, is required to be dispatched to the Shareholders within 15 business days after the publication of this announcement, which shall be on or before July 3, 2023.

**Completion of the Equity Investment is subject to the satisfaction and/or waiver of the conditions precedent therein. In addition, the Equity Transfer and Capital Injection Agreement and the Shareholders Agreement may be terminated in certain circumstances. Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.**

#### **INTRODUCTION**

The Board is pleased to announce that on June 10, 2023, the Company (together with certain subsidiaries) and Mr. Mao entered into the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents with the Investors, pursuant to which the Investors have conditionally agreed to (i) inject approximately RMB547.72 million (equivalent to approximately US\$77.34 million) in aggregate into VIVA Shanghai, of which approximately US\$8.23 million will be accounted as paid-in registered capital of VIVA Shanghai, while the balance of approximately US\$69.11 million will be accounted as its capital reserve; and (ii) acquire approximately US\$7.74 million of the registered capital of VIVA Shanghai from Viva Investment for a consideration of approximately RMB514.60 million (equivalent to approximately US\$72.66 million) in aggregate (together, the **"Equity Investment"**). The total consideration of the Equity Investment amounted to approximately RMB1,062.32 million.

## **THE EQUITY TRANSFER AND CAPITAL INJECTION AGREEMENT**

### **Date**

June 10, 2023

### **Parties to the Equity Transfer and Capital Injection Agreement**

- (1) the Company Side, including the Company, Viva Biotech, Viva Investment, VIVA Shanghai, SYNthesis HK and Viva Sichuan;
- (2) Mr. Mao; and
- (3) the Investors, including HLC SPV, Qingdao Hongyi, Daxue Investments and True Light P.

### **The Equity Investment**

The Investors conditionally agreed to:

- (1) inject RMB547,718,457 (equivalent to approximately US\$77.34 million) in aggregate into VIVA Shanghai, of which US\$8,234,671 will be accounted as paid-in registered capital of VIVA Shanghai, while the balance will be accounted as its capital reserve. In particular, (i) HLC SPV will subscribe for registered capital of US\$1,490,754 for a consideration of US\$14,000,875; (ii) Qingdao Hongyi will subscribe for registered capital of US\$775,163 for a consideration of RMB51,558,950; (iii) Daxue Investments will subscribe for registered capital of US\$4,775,003 for a consideration of RMB317,603,131; and (iv) True Light P will subscribe for registered capital of US\$1,193,751 for a consideration of RMB79,400,783; and
- (2) acquire US\$7,736,700 of the registered capital of VIVA Shanghai from Viva Investment for a consideration of RMB514,596,543 (equivalent to approximately US\$72.66 million) in aggregate. In particular, (i) HLC SPV will acquire registered capital of US\$1,400,605 for a consideration of US\$13,154,206; (ii) Qingdao Hongyi will acquire registered capital of US\$728,287 for a consideration of RMB48,441,050; (iii) Daxue Investments will acquire registered capital of US\$4,486,247 for a consideration of RMB298,396,869; and (iv) True Light P will acquire registered capital of US\$1,121,561 for a consideration of US\$74,599,217.

Immediately after completion of the Equity Investment, the Investors will be interested in approximately 24.21% of the enlarged registered capital of VIVA Shanghai in aggregate, and the Group's interest in VIVA Shanghai will be diluted from 100% to approximately 75.79%. According to Rule 14.29 of the Listing Rules, the relevant dilution is considered to be a deemed disposal of the Company's interest in a subsidiary. VIVA Shanghai remains as a subsidiary of the Company upon completion of the Equity Investment.

### **Subscription price and basis of determination**

The total consideration of the Equity Investment was determined based on arm's length negotiations between the parties with reference to, among other things, the business prospects and financial conditions of VIVA Shanghai and the CRO Business, the Internal Corporate Restructuring initiated by the Company and the possibility of the Qualified IPO. In determining the consideration, the Company and the Investors have taken into account the revenue ratios (equals to the market value divided by the revenue) and gross profit ratios (equals to the market value divided by gross profit) of other comparable companies listed on the Stock Exchange, the Shanghai Stock Exchange or the Shenzhen Stock Exchange (the "Comparables") which are also engaged in the CRO Business similar to the Group.

The Company is of the view that the consideration to be fair and reasonable based on the above determination factors; in particular, such consideration implies a revenue ratio and gross profit ratio of approximately 4.90x and 11.04x with reference to (i) total consideration of the Equity Investment, and (ii) the revenue and gross profit of the CRO Business of the Group for the year ended December 31, 2022 as disclosed in the annual report of the Company for the year 2022 (i.e. approximately RMB895.1 million and RMB397.3 million for the segment revenue and segment results for CRO Business, respectively). The above ratios are at the similar level of the average revenue ratios and gross profit ratios of other Comparables in the year 2022, which are approximately 4.57x and 11.87x, respectively.

### **Payment of the consideration**

The total consideration of the Equity Investment amounted to approximately RMB1,062.32 million. The Investors shall settle the total consideration of the Equity Investment upon Completion in cash. If VIVA Shanghai records net liabilities as of the date of Completion, the Company and Viva Biotech shall jointly and severally pay such amount to VIVA Shanghai to the effect that VIVA Shanghai does not have any net liabilities as of the date of Completion.

### **Conditions precedent**

The completion of the Equity Investment (the "Completion") is conditional upon fulfillment of, among other things, the following conditions (the "Conditions Precedent"), unless otherwise agreed to be waived by the relevant parties of the respective Conditions Precedent:

- (1) the representations and warranties made by the Company Side and Mr. Mao are true, accurate, complete, without omission and not misleading in all material respects at the time they are made and at and as of the date of Completion, with the same effect as if such representations and warranties had been made at and as of the time of the Completion, except in any case where the representations and warranties are made with respect to matters as of a particular date only, such representations shall be true, accurate and not misleading in all material respects as of that particular date;
- (2) each party of the Company Side and Mr. Mao has performed and complied in all respects with all commitments and obligations contained in the Transaction Documents that are required to be performed or complied with by such party on or before the date of Completion;

- (3) the Board and the Shareholders at the general meeting of the Company have approved (as applicable) (i) the Equity Investment and the Internal Corporate Restructuring, (ii) the execution of each of the Transaction Documents by the Company and performance of its obligations thereunder; and the Company has discharged its disclosure obligations required by applicable laws and security regulatory authorities;
- (4) (i) all of the Transaction Documents in connection with the Equity Investment have been duly executed by the relevant parties; (ii) all governmental agency approvals, notifications, filings or registrations and third-party consents or notification required for the execution or performance of the Equity Transfer and Capital Injection Agreement or completion of the Equity Investment by each party of the Company Side (save for certain bank consents) have been obtained from or given to the appropriate governmental agencies or third parties; and (iii) no applicable laws or governmental orders have been enacted, promulgated, enforced or approved by any governmental agencies that would render the transactions contemplated under the Transaction Documents unlawful or otherwise restrict or prohibit the transactions contemplated by the Transaction Documents;
- (5) the shareholders' meeting and the board of directors of VIVA Shanghai have approved (i) the entering into of the Transaction Documents and the completion of the proposed transactions under the Transaction Documents, (ii) the amendment of the articles of association of VIVA Shanghai, (iii) the appointment of each candidate nominated by HLC SPV and/or Qingdao Hongyi and Daxue Investments respectively as directors of VIVA Shanghai); and the existing shareholders of VIVA Shanghai have agreed to waive their pre-emptive rights and right of first refusal in respect of the Equity Investment and other similar rights (if any);
- (6) VIVA Shanghai has obtained the new business license and completed the company registration and change procedures in connection with the Equity Investment, including (i) the registration and filing of the articles of association of VIVA Shanghai, (ii) the registration of the Investors as shareholders of VIVA Shanghai, (iii) the registration of the candidates nominated by the Investors as directors of VIVA Shanghai, (iv) the change of foreign investment information with the competent department of commerce, (v) the registration of change in foreign exchange with the competent department of foreign exchange (or its authorized bank); and (vi) opening of capital account for receiving the capital injection;
- (7) there has been no material adverse change in the condition (financial or otherwise, but shall not include the effect of fluctuations in the share price of the Company), results of operations, assets, regulatory status, business or prospects of the Target Group and the Company Side as a whole; and no event or events have occurred that, individually or in combination, have had a material adverse effect and it is reasonable to expect that no such event or events will occur that could, individually or in combination, have a material adverse effect. In terms of the convertible bonds falling under the scope of the Company's material contracts, no bond holders has demanded the Company to redeem the convertible bonds held by it;

- (8) the Target Group and Company Side have discharged or procured others to discharge certain obligations to the satisfaction of the Investors, including (i) implementation of the Internal Corporate Restructuring, (ii) VIVA Shanghai's adoption of share incentive plan and management subscription plan; (iii) adjustments of employment relationship with certain employees of VIVA Shanghai; (iv) settlement of related party loans or advances; (v) communication with certain lending banks in connection with the Equity Investment; (vi) Mr. Mao and Ms. Jun MAO entering into certain undertakings in connection with the Equity Investment; and (vii) provision of certain financial information of members of the Target Group required as part of the due diligence exercise;
- (9) the representations and warranties made by the Investors are true, accurate and not misleading in all material respects at the time they are made, and are true, accurate, and not misleading in all material respects at and as of the date of the Completion, with the same effect as if such representations and warranties had been made at and as of the time of the Completion, except in any case where the representations and warranties are made with respect to matters as of a particular date only, such representations shall be true, accurate and not misleading in all material respects as of that particular date; and
- (10) the Investors have performed and complied in all material respects with all commitments and obligations contained in the Transaction Documents that must be performed or complied with by such party on or before the date of Completion.

### **Completion**

Completion of the Equity Investment will take place on the tenth business days after the date on which all of the Conditions Precedent (save for those to be fulfilled or waived on the date of Completion) have been fulfilled (or waived by the Investors), or any other date as agreed by the Investors.

### **Pre-Completion undertakings**

Each party of the Company Side has provided certain pre-Completion undertakings, including (but not limited to): (i) implementing the Internal Corporate Restructuring to the stage as agreed with the Investors; (ii) promptly notifying the Investors upon the occurrence of certain material adverse events; (iii) each member of the Target Group conducting its business operations in a manner consistent with past practice and in the normal course of business operations; (iv) procuring members of the Target Group not to take certain actions (including but not limited to amending its articles of association, issue of securities, change of principal business, distribution of dividend and change of accounting standards) without obtaining prior written consents of the Investors; and (v) cooperating with the due diligence exercise of the Investors and its advisers. Mr. Mao undertakes to comply with his undertaking provided, and procure Ms. Jun Mao to comply with her undertaking provided.

## **Post-Completion undertakings**

Mr. Mao and members of the Company Side has provided certain post-Completion undertakings, including (but not limited to): (i) complying with applicable laws and regulations in its business operation; (ii) completing the Internal Corporate Restructuring; (iii) procuring Ms. Jun MAO to comply with her undertaking provided, and using its reasonable efforts to file the application for the Qualified IPO as agreed with the Investors by June 30, 2024 and making pre-consultation with the relevant stock exchange as soon as possible and within three months after the date of Completion on VIVA Shanghai's suitability for the Qualified IPO; (iv) completing the share pledge registration procedures as required under the Shareholders Agreement (as disclosed below); (v) adopting and implementing the share incentive plan and management subscription plan to be further agreed with the Investors; (vi) Target Group to comply with the relevant Qualified IPO application and suitability requirements implemented by the relevant stock exchange based on the progress of its Qualified IPO application preparation; (vii) using its best efforts to procure that VIVA Shanghai's proposed Qualified IPO application shall be conducted in accordance with the requirements under the Listing Rules (including but not limited to the Practice Note 15 of the Listing Rules); and (viii) ensuring that the Target Group will comply with the applicable laws, listing rules of the relevant stock exchange in connection with the Qualified IPO, the Listing Rules and the requests of the intermediaries of the listing application to rectify the issues that may affect the Target Group's Qualified IPO.

## **Termination**

The Equity Transfer and Capital Injection Agreement shall be effective upon the date of execution and may be terminated under the following circumstances before Completion:

- (1) Equity Transfer and Capital Injection Agreement may be terminated by unanimous written consent of the parties thereto;
- (2) If the Conditions Precedent are not satisfied or waived on or before November 30, 2023 (or a later date as agreed by the parties), any party of the Company Side or any Investor who have fulfilled all the applicable Conditions Precedents shall be entitled to terminate the Equity Transfer and Capital Injection Agreement;
- (3) If, during the period from the date of the Equity Transfer and Capital Injection Agreement to the date of Completion, (i) an event or circumstance occurs which has caused or is likely to cause a material adverse effect or any of the Conditions Precedent has been determined as unable to be satisfied or has been breached and is not waived by the Investors, or (ii) VIVA Shanghai has been assigned for the benefit of its creditors, or VIVA Shanghai initiates or is subject to any legal proceedings with a view to declaring VIVA Shanghai in criminal proceedings, bankruptcy or insolvency, or with a view to liquidation, winding up, reorganization or restructuring of its liabilities under any law in connection with bankruptcy, insolvency or reorganization, the Equity Transfer and Capital Injection Agreement may be unilaterally terminated by any Investor;
- (4) If any governmental agency issues an order, decree or ruling, or takes any other action, restricting, preventing or otherwise prohibiting the transactions contemplated under the Equity Transfer and Capital Injection Agreement, and such order, decree, ruling or other action is final and not subject to review, prosecution or appeal, then either the Investors, or the Company Side and Mr. Mao may terminate the Equity Transfer and Capital Injection Agreement; and

- (5) Any complying party may terminate the Equity Transfer and Capital Injection Agreement by giving notice to VIVA Shanghai and the defaulting party if the defaulting party has made a material misrepresentation or has committed a material breach of a promise or covenant contained in the Equity Transfer and Capital Injection Agreement and such breach, if curable, is not cured within thirty (30) days after notice stating the reason and intent for termination is given.

Certain provisions relating to confidentiality, expenses and taxation, liabilities of breach and remedies, governing law and other ancillary provisions in the Equity Transfer and Capital Injection Agreement shall still be legally binding on parties to the Equity Transfer and Capital Injection Agreement after its termination.

## **THE SHAREHOLDERS AGREEMENT**

### **Date**

June 10, 2023

### **Parties to the Shareholders Agreement**

- (1) Mr. Mao;
- (2) the Company;
- (3) Viva Biotech;
- (4) VIVA Shanghai;
- (5) the Investors, including HLC SPV, Qingdao Hongyi, Daxue Investments and True Light P.

### **Shareholders' rights and obligations**

The Shareholders Agreement sets out the rights and obligations of the parties thereto in relation to the management and operations of VIVA Shanghai and shall take effect upon the Completion. In particular, it contains the following key provisions in relation to the Investors' rights and obligations as a shareholder of VIVA Shanghai:

#### ***Restrictions on equity transfer***

Without the prior written consent of the Investors, Mr. Mao, the Company, Viva Biotech and any employee stock ownership platform (“**ESOP**”) (including its general or limited partners) (the “**Restricted Shareholders**”) shall not directly or indirectly transfer, pledge or otherwise dispose of their interest held directly or indirectly in VIVA Shanghai prior to the completion of the Qualified IPO.

Prior to the completion of the Qualified IPO, the Restricted Shareholders shall not, except with the prior written consent of the Investors, directly or indirectly transfer any equity interests in VIVA Shanghai to third parties other than the Investors at a lower price per share than the benchmark price of RMB66.5137 per share (the “**Benchmark Price**”, being the price paid by the Investors for acquiring US\$1.0 in the registered capital of VIVA Shanghai in the Equity Investment, calculated with reference to the total consideration of the Equity Investment and the registered capital acquired and subscribed in aggregate). Any Investor who consents to such transfer shall also be entitled to enforce the anti-dilution measures as explained below, and Restricted Shareholders shall not conduct such transfer prior to the completion of the anti-dilution measures.



The above restrictions on equity transfer do not apply to (i) transfer of equity interests in VIVA Shanghai among the ESOPs, the transfer of partnership interest among partners at the ESOP level, or the repurchase by the ESOPs or its partners of partnership interest held by other partners for the purpose of implementing any share incentive scheme validly approved by shareholders of VIVA Shanghai; and (ii) transfer of Shares by partners of the ESOPs (other than Mr. Mao) through the open market, provided that such transfer does not affect the stability of control of the Target Group.

***Pre-emptive right, right of first refusal and tag-along rights***

The Investors shall enjoy the pre-emptive right, right of first refusal and tag-along rights that are customary and not subordinated to other shareholders of VIVA Shanghai.

***Transfer of equity interest by the Investors***

The Investors may transfer, in whole or in part, their equity interest in VIVA Shanghai to any third party (other than competitors of the Group as agreed among the parties) without the consent of other shareholders of VIVA Shanghai and not subject to any right of first refusal, tag-along right or any lock-up period.

***Anti-dilution***

VIVA Shanghai shall not increase its registered capital or issue any equity securities unless approved by its shareholders. If any capital increase of VIVA Shanghai were conducted at a new price (“**Lower Price**”) lower than the Benchmark Price (except for the addition of registered capital as a result of the implementation of the employee share incentive scheme, conversion of any convertible equity securities, subscription of new registered capital pursuant to the anti-dilution measures and capitalization issue). The Investors shall be entitled to demand VIVA Shanghai and Viva Biotech to adopt the anti-dilution measures such as making cash compensation or distribution of special dividend to the effect that the Benchmark Price can be adjusted to the same as the Lower Price.

***Repurchase obligations***

The Investors shall have the right to demand VIVA Shanghai, VIVA Biotech and the Company to repurchase the equity interest held by the Investors in VIVA Shanghai upon the following circumstances (the “**Repurchase Obligations**”):

- (1) VIVA Shanghai fails to complete the Qualified IPO on or before December 31, 2026;
- (2) VIVA Shanghai is not acquired or merged by others on or before December 31, 2026, where the consideration for such merger or acquisition is not less than 1.5 times of the post-money valuation subsequent to the Equity Investment;
- (3) there is a change in de facto controller of the Company, Viva Biotech or VIVA Shanghai;
- (4) there is substantial impediment to the Qualified IPO due to the failure of Mr. Mao, Ms. Min ZHOU and/or Ms. Jun MAO in discharging their undertakings provided in the Transaction Documents;

- (5) there is material breach of any of the undertakings, representations and warranties under the Transaction Documents by Mr. Mao, VIVA Shanghai, Viva Biotech and/or the Company, resulting in material losses suffered by the Target Group or the Investors, leading to the Investors' failure to realize its investment purpose; and
- (6) any other shareholders of VIVA Shanghai demand the relevant obligor to repurchase or acquire any equity interest held by it in VIVA Shanghai pursuant to any agreement between it and VIVA Shanghai or Viva Biotech or applicable laws.

Under the circumstances (1), (2), (3) and (6) above (where circumstance (6) is triggered by circumstances (1) to (3)), the repurchase price should be calculated in accordance with the formula below:

*Repurchase price = consideration paid by the relevant Investor in the Equity Investment  $\times$  (1+10% $\times$  N) + all cumulative declared but unpaid dividends – dividends paid to such Investor attributable to the equity interest acquired or subscribed by such Investor under the Equity Investment*

Under the circumstances (4), (5) and (6) above (where circumstance (6) is triggered by circumstances (4) and (5)), the repurchase price should be calculated in accordance with the formula below:

*Repurchase price = consideration paid by the relevant Investor in the Equity Investment  $\times$  (1+15% $\times$  N) + all cumulative declared but unpaid dividends – dividends paid to such Investor attributable to the equity interest acquired or subscribed by such Investor under the Equity Investment*

The above "N" refers to the number of years from the Date of Completion of the Equity Investment to the date on which the Investors receive the repurchase price in full, which shall be calculated by dividing the actual number of days by 365 days in the case of less than one year.

### ***Share pledge***

For the purpose of securing full performance of the Repurchase Obligations, including but not limited to full payment of the repurchase price and other fees, costs, expenses and disbursements incurred to obtain such repurchase price, Viva Biotech agrees to pledge its entire equity interest in VIVA Shanghai to the Investors. The relevant parties shall sign an equity (or share) pledge agreement that is reasonably satisfactory to the Investors.

### ***Most-favored-nation treatment***

The Investors shall be entitled to any terms and conditions in any future or existing financing of VIVA Shanghai that are more favorable than those provided under the Equity Investment.

### ***Board seats***

Upon completion of the Equity Investment, the Investors may appoint two (2) directors to the board of directors of VIVA Shanghai, where Viva Biotech shall appoint three (3) directors, including the general manager/chief executive officer of the Target Group. Certain significant matters of VIVA Shanghai such as (i) formulating proposals of change in registered capital or debt issue; (ii) formulating proposals for merger, demerger, dissolution or change in corporate form; (iii) approving the sale, pledge or other disposal of any assets of VIVA Shanghai (including but not limited to intellectual property rights) exceeding RMB10 million individually or RMB25 million in aggregate during the financial year, which is outside the approved annual budget and business plan; and (iv) approving the incurrence of any liabilities, guarantees, expenses, external investments (including the establishment of subsidiaries) or other transactions outside the approved annual budget and business plan exceeding RMB10 million individually or RMB25 million in aggregate during the financial year shall be approved by the board of directors of VIVA Shanghai with at least one affirmative vote from directors nominated by the Investors.

### ***Investors' consent right***

Certain significant matters of VIVA Shanghai such as (i) amendments of articles of association, (ii) change in registered capital; (iii) change in de facto controller, principal business or corporate form, and conducting merger, demerger or dissolution; (iv) issue of any preferred shares or convertible securities; (v) change in the board seats and the director appointment procedures; (vi) entering into any related party transactions with its shareholders, directors, senior management and other external related parties (other than those related parties transaction approved with at least one affirmative vote from the Investors in the VIVA Shanghai annual budget); (vii) establishment of and amendment of any employee incentive schemes and proposals; and (viii) application for Qualified IPO or other form of public share offering, shall be approved at the general meetings of VIVA Shanghai with at least one affirmative vote from the Investors.

### ***Information and inspection rights***

Subject to the compliance with applicable laws, regulations, regulatory documents and the relevant requirements of the supervisory and regulatory authorities of the place of listing, VIVA Shanghai shall provide the following documents to the Investors:

- (1) its consolidated annual financial statements prepared in accordance with PRC accounting standards and audited by an independent auditor and an annual business operation report within four months after the end of each financial year;
- (2) its consolidated interim financial statements prepared in accordance with PRC accounting standards and reviewed by an independent auditor within three months after the end of the second quarter of each financial year;
- (3) its consolidated financial statements prepared in accordance with PRC accounting standards and quarterly business operation report within 45 days after the end of each quarter of each financial year; and
- (4) other business and financial information as each Investor may reasonably request.

Any Investor shall have the right, without affecting the normal business operation of the Target Group and by giving two business days' written notice, to inspect over the premises, equipment, books and records of the Target Group, and have the right to discuss business, financial position and operations of members of the Target Group with its directors, officers and advisers.

### **Qualified IPO**

VIVA Shanghai shall issue and list its shares on a domestic stock exchange in the PRC (excluding a listing on the National Equities Exchange and Quotations System and the Beijing Stock Exchange). If any special rights of any shareholder under the Shareholders Agreement become a legal impediment to the Qualified IPO of VIVA Shanghai, parties agree to enter into written agreements to amend, terminate or cease to enforce such special rights as and when appropriate. Parties to the Shareholders Agreement shall fully cooperate in the application process of the Qualified IPO.

### **FINANCIAL EFFECTS OF THE EQUITY INVESTMENT**

Upon the completion of the Equity Investment, the total registered capital of VIVA Shanghai will be increased to US\$65,971,371, of which 75.79%, 4.38%, 2.28%, 14.04% and 3.51% of the total equity interest of VIVA Shanghai will be owned by the Company through Viva Biotech, HLC SPV, Qingdao Hongyi, Daxue Investments and True Light P, respectively. Hence, the Group's interest in VIVA Shanghai will be diluted from 100% to 75.79% after the completion of the Equity Investment and VIVA Shanghai will remain a subsidiary of the Company.

The Equity Investment is expected to be recorded as an equity transaction in accordance with International Financial Reporting Standards and the accounting policies of the Group. The Directors do not expect to recognize any gain/loss from the transactions contemplated under the Equity Transfer and Capital Injection Agreement. Shareholders should note that the actual amount of gain/loss from the Equity Investment to be recorded by the Company (if any) will be subject to review by the auditor of the Company.

### **INFORMATION OF THE GROUP AND VIVA SHANGHAI**

#### **The Group**

The Group provides one-stop services, consisting of CRO business and CDMO business, ranging from early-stage structure-based drug research and development to commercial drug delivery to global biopharmaceutical innovators. The services of CRO business cover customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. The services of CDMO business offer worldwide pharmaceutical and biotech partners comprehensive services from drug development through commercial drug manufacturing.

## VIVA Shanghai

VIVA Shanghai is a company established in the PRC with limited liability and an indirect wholly-owned subsidiary of the Company as at the date of this announcement, which is principally engaged in the CRO Business. Set out below is a summary of the unaudited financial information of VIVA Shanghai for the two years ended December 31, 2021 and December 31, 2022 respectively, prepared in accordance with International Financial Reporting Standards:

	<b>For the year ended December 31, 2022</b> (Unaudited) <i>RMB' 000</i> ( <i>approximately</i> )	<b>For the year ended December 31, 2021</b> (Unaudited) <i>RMB' 000</i> ( <i>approximately</i> )
Profit before taxation	<b>248,713</b>	250,295
Profit after taxation	<b>202,193</b>	206,297
Net asset	<b>1,158,764</b>	731,836

## Internal Corporate Restructuring

The Group had two reportable operating segments, being (i) drug discovery services (“**CRO Business**”) and (ii) CDMO and commercialization services (“**CDMO Business**”). It also makes strategic investments in biotechnology startup companies with potentials for future cooperation (the “**Incubation Portfolio Companies**”). For the purpose of clearly delineating its business segments and streamlining its business operations, the Group has resolved to conduct certain internal corporate restructuring, upon the completion of which (i) all assets and related personnel of the Group’s CRO Business will be transferred to VIVA Shanghai and its subsidiaries; and (ii) all assets and related personnel of the Group’s CDMO Business will be transferred from VIVA Shanghai to other wholly-owned subsidiaries of the Group. Following the completion of the Internal Corporate Restructuring, the Group will conduct its CRO Business and CDMO Business and hold its equity interests in the Incubation Portfolio Companies through separate groups of subsidiaries. It is currently contemplated that the Group will not be subject to any disclosure or approval requirements under Chapter 14 of the Listing Rules in conducting the Internal Corporate Restructuring. The Group will fully comply with the Listing Rules in conducting the Internal Corporate Restructuring and publish further announcement(s) in compliance with the applicable requirements under the Listing Rules as and when appropriate.

## INFORMATION OF INVESTORS

### HLC SPV

HLC SPV is a company incorporated in Hong Kong, and is owned and controlled by HLC VGC. HLC VGC is an exempted limited partnership formed under the laws of the Cayman Islands, whose primary purpose is to make equity investments with a focus on healthcare, industrial materials and equipment manufacturing. HLC VGC is an affiliate of HighLight Capital. The general partner of HLC VGC is HLC VGC GP IV Limited, which is ultimately owned by Mr. Wang Hui. None of the limited partners of HLC VGC held more than 10% of the limited partnership interest therein. HighLight Capital is a private investment firm dedicated to creating long-term values through promoting technology innovations. With an aggregate of over US\$3 billion of assets under management as of the date of this announcement, its portfolio companies include some of today's most influential brands in their respective sectors, such as Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (stock code: 300760.SZ), Pharmaron Beijing Co., Ltd. (stock code: 300759.SZ) and Hangzhou Tigermed Consulting Co., Ltd. (stock code: 03347.HK).

### Qingdao Hongyi

Qingdao Hongyi is a limited partnership established in the PRC in 2022, whose primary purpose is to make equity investments with a focus on healthcare, industrial materials and equipment manufacturing. The general partner of Qingdao Hongyi is Shanghai Hehong Jinghui Equity Investments Management Co., Ltd. (上海合弘景暉股權投資管理有限公司) (“**Shanghai Hehong**”), which is an affiliate of HighLight Capital. Shanghai Hehong is controlled by Mr. Wang Hui. None of the ultimate beneficial owners of Qingdao Hongyi is interested in more than 10% of the limited partnership interest therein. HighLight Capital is a private investment firm dedicated to creating long-term values through promoting technology innovations. With an aggregate of over US\$3 billion of assets under management as of the date of this announcement, its portfolio companies include some of today's most influential brands in their respective sectors, such as Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (stock code: 300760.SZ), Pharmaron Beijing Co., Ltd. (stock code: 300759.SZ) and Hangzhou Tigermed Consulting Co., Ltd. (stock code: 03347.HK).

### Daxue Investments

Daxue Investments is a private company limited by shares incorporated in Singapore in 2023. Daxue Investments is indirectly wholly owned by Temasek Holdings (Private) Limited (“**Temasek**”). Temasek is an investment company with a net portfolio value of S\$403 billion (RMB1.89 trillion) as at March 31, 2022. Headquartered in Singapore, it has 12 offices in 8 countries around the world. Temasek's Purpose “So Every Generation Prospers” guides it to make a difference for today's and future generations. The Temasek Charter defines its three roles as an Investor, Institution and Steward, and shapes its ethos to do well, do right and do good.

## **True Light P**

True Light P is a private company limited by shares incorporated in Singapore in 2021. True Light P is indirectly wholly held by True Light Capital GP Pte. Ltd. (“**True Light GP**”) in its capacity as general partner of True Light Fund I LP (“**True Light Fund**”). True Light GP has appointed True Light Capital Pte. Ltd. (“**True Light Capital**”) as the investment manager of True Light Fund. Both True Light GP and True Light Capital are each indirectly wholly owned by Temasek. True Light Capital has its own independent board and management and makes its own investment decisions. True Light Capital invests in high-quality investment opportunities which have a nexus to or have a major business relationship with China, across asset classes, sectors, and stages.

To the best of the Directors’ knowledge, information and belief having made all reasonable enquiry, as of the date of this announcement, each of the Investors and their respective ultimate beneficial owner(s) is a third party independent of the Company and its connected persons.

## **USE OF PROCEEDS**

The gross proceeds from the Equity Investment are approximately RMB1,062.32 million and the net proceeds (after the deduction of related transaction expenses) are expected to be approximately RMB1,058.33 million. The Company intends to apply such proceeds to redeem the December 2025 Convertible Bonds on December 30, 2023 (at the option of the bondholders) at 103.08% of its principal amount, together with interest accrued but unpaid.

## **REASONS FOR AND BENEFITS OF THE EQUITY INVESTMENT**

On December 17, 2020, Viva Investment, a wholly-owned subsidiary of the Company, issued the December 2025 Convertible Bonds in an aggregate principal amount of US\$280,000,000, which were guaranteed by the Company. The conversion period is on or after February 9, 2021 up to the close of business on the 10th day prior to December 30, 2025 and the price of ordinary shares of the Company to be issued in exercise of the right of conversion is initially HK\$11.637 per Share. On December 30, 2023, Viva Investment would, at the option of the bondholders, redeem all or some only of such holder’s bonds on December 30, 2023 at 103.08% of its principal amount, together with interest accrued but unpaid.

The Company intended to apply the net proceeds from the Equity Investment to redeem the December 2025 Convertible Bonds upon the exercise of the put options by the bond holders, which will allow the Group to settle its outstanding liabilities without occupying its internal resources, and thus optimizing its capital structure, lowering its financial risks, enhancing its financing capability in the future and providing strong working capital support for its operations and development to meet the requirements of its business growth.

In accordance with the Company's development strategy of CRO Business, separating the CRO Business and CDMO Business into two distinct companies will deliver benefits to both businesses as they grow. Each business group shall also have enhanced financial flexibility when running the different businesses that have distinct capital allocation needs, this also enables the management of each to pursue their own specific and focused strategy. The Company has initiated the Internal Corporate Restructuring and researched the possibility of Qualified IPO. The Qualified IPO is still in its early discussion and no concrete plan has yet crystallised as of the date of this announcement. By introducing the Investors as shareholders of VIVA Shanghai, the Group will be able to benefit from the Investors' industry resources, further promote its industry positioning and broaden its independent financing channels.

Taking into account the factors mentioned above, the Board consider that the terms and conditions of the Equity Transfer and the Capital Injection Agreement and the Shareholders Agreement and the Equity Investment as contemplated thereunder are fair and reasonable, on normal commercial terms and in the interests of the Company and the Shareholders as a whole.

### **LISTING RULES IMPLICATIONS**

VIVA Shanghai is an indirect wholly-owned subsidiary of the Company as at the date of this announcement. It is contemplated that the percentage of the Group's shareholding interest in VIVA Shanghai will reduce to 75.79% following the completion of the Equity Investment by the Investors. The Equity Investment, if materialized, may constitute a deemed disposal by the Company under Rule 14.29 of the Listing Rules.

Since one of the applicable percentage ratios (as defined under the Listing Rules) in respect of the Equity Investment and the transactions contemplated thereunder (taking into account the Repurchase Obligations of VIVA Shanghai and Viva Biotech) exceeds 25% but all are less than 75%, the Equity Investment constitutes a major transaction of the Company under Chapter 14 of the Listing Rules, and is subject to the reporting, announcement, circular and shareholders' approval requirements under the Listing Rules.

As the Repurchase Obligations is not at the Company's discretion, such right of the Investors is treated as if it had been exercised upon the execution of the Equity Transfer and Capital Injection Agreement and the Shareholders Agreement under Rule 14.74 of the Listing Rules. The Company will publish an announcement as soon as reasonably practicable should the Investors exercise such right.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, none of the Directors has any material interest in the Equity Investment. Although Mr. Mao is one of the signing parties to the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents, he is in the capacity of a founder of the Group to provide undertakings to the Investors and does not have material interest in the Equity Investment. Therefore, none of the Directors is required to abstain from voting on the relevant resolution approving the Equity Investment at the Board meeting.



To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, none of the Shareholders has any material interest in the Equity Investment as contemplated under the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents. Pursuant to Rule 17.05A of the Listing Rules, the trustee holding unvested shares of a share scheme, whether directly or indirectly, shall abstain from voting on matters that require shareholders, approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner's direction and such a direction is given. Nevertheless, pursuant to the Viva Biotech Holdings Restricted Share Unit Scheme, its trustee shall not exercise the voting rights attached to the Shares held by it. Therefore, none of the Shareholders and their associates is required to abstain from voting in the general meeting to be convened by the Company for the approval of the Equity Investment as of the date of this announcement.

## **DISPATCH OF CIRCULAR**

The Company will convene a general meeting for the purpose of, among other things, considering, and if thought fit, approving the entering into of the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents and the Equity Investment as contemplated thereunder. Pursuant to Rule 14.41(a) of the Listing Rules, a circular containing, *inter alia*, (i) further details of the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and other Transaction Documents; (ii) financial information of the Company; and (iii) other information as required by the Listing Rules, together with the notice of the general meeting, is required to be dispatched to the Shareholders within 15 business days after the publication of this announcement, which shall be on or before July 3, 2023.

**Completion of the Equity Investment is subject to the satisfaction and/or waiver of the conditions precedent therein. In addition, the Equity Transfer and Capital Injection Agreement and the Shareholders Agreement may be terminated in certain circumstances. Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.**

*For illustration purposes only, in this announcement, the conversion of HK\$ into US\$ is based on the exchange rate of HK\$7.83661 to US\$1.00000; the conversion of RMB into US\$ is based on the exchange rate of RMB7.0821 to US\$1.0000; and the conversion of HK\$ into RMB is based on the exchange rate of HK\$1.00000 to RMB0.90372.*

## DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context otherwise requires:

“Board”	the board of Directors of the Company
“CDMO”	contract development manufacture organization
“Company”	Viva Biotech Holdings (维亚生物科技控股集团), a company incorporated in the Cayman Islands as an exempted company with limited liability, the issued shares of which are listed on the Main Board of the Hong Kong Stock Exchange (stock code: 1873)
“Company Side”	the Company, Viva Biotech, Viva Investment, VIVA Shanghai, Viva Sichuan and SYNthesis HK
“CRO”	contract research organization
“Daxue Investments”	Daxue Investments Pte. Ltd., a private company limited by shares incorporated in Singapore in 2023
“December 2025 Convertible Bonds”	US\$280 million 1.00% guaranteed convertible bonds due 2025 issued by Viva Investment convertible at the option of the holder thereof into fully paid ordinary Shares of the Company of par value US\$0.000025 each at the initial conversion price of HK\$11.6370 per Share
“Director(s)”	the director(s) of the Company
“Equity Investment”	the proposed acquisition of equity interest and capital injection in VIVA Shanghai by the Investors as contemplated under the Equity Transfer and Capital Injection Agreement
“Equity Transfer and Capital Injection Agreement”	the equity transfer and capital injection agreement dated June 10, 2023 entered into among the Company Side, Mr. Mao and the Investors in connection with the transfer of equity interest and injection of capital in VIVA Shanghai
“Group”	the Company and its subsidiaries

“HK\$”	Hong Kong dollar(s), the lawful currency of Hong Kong
“HLC SPV”	HLC VGC Partners HK II Limited, a limited company incorporated in Hong Kong in 2022
“HLC VGC”	VGC Fund IV L.P.
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“independent third party(ies)”	the independent third party who is, to the best of the Directors’ knowledge, information and belief having made all reasonable enquiry, independent of and not connected with the Company and the connected person(s) of the Company
“Internal Corporate Restructuring”	The internal restructuring of the Group’s CRO Business and CDMO Business, details of which have been disclosed in the Company’s announcement dated June 10, 2023 in relation to the proposed issue of convertible bonds under general mandate
“Investors”	HLC SPV, Qingdao Hongyi, Daxue Investments and True Light P, each an “Investor”
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Mr. Mao”	Mr. MAO Chen Cheney (毛晨), an executive Director and chairman of the Board. As of the date of this announcement, Mr. Mao, together with his associates, controls approximately 30.46% of the total issued share capital of the Company and is the de facto controller of the Company, Viva Biotech or VIVA Shanghai for the purpose of the Equity Transfer and Capital Injection Agreement and the Shareholders Agreement
“PRC”	the People’s Republic of China, excluding for the purpose of this announcement, Hong Kong, Macau Special Administrative Region of the PRC and Taiwan
“Qingdao Hongyi”	Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) (青島弘熠投資合夥企業(有限合夥)), a limited partnership established in the PRC in 2022

“Qualified IPO”	an initial public offering of the shares of VIVA Shanghai on a domestic stock exchange in the PRC (excluding a listing on the National Equities Exchange and Quotations System and the Beijing Stock Exchange)
“RMB”	renminbi, the lawful currency of the PRC
“S\$”	Singapore dollars, the lawful currency of Singapore
“Shares”	the shares of the Company
“Shareholders”	the holders of Shares
“Shareholders’ Agreement”	the shareholders agreement dated June 10, 2023 entered into among the Company, Mr. Mao, Viva Biotech, VIVA Shanghai and the Investors
“SYNthesis HK”	SYNthesis med chem (Hong Kong) Limited, a limited company incorporated in Hong Kong and a direct wholly-owned subsidiary of the Company
“Target Group”	VIVA Shanghai and its subsidiaries
“Transaction Documents”	the Equity Transfer and Capital Injection Agreement, the Shareholders Agreement and the other documents or agreements entered into or delivered in connection with the Equity Investment by and among the Company (and their subsidiaries and affiliates, if applicable), on the one hand, and the Investors (and their subsidiaries and affiliates, if applicable), on the other hand
“True Light P”	True Light Investments P Pte. Ltd., a private company limited by shares incorporated in Singapore in 2021
“US\$”	US dollar(s), the lawful currency of the United States
“Viva Biotech”	Viva Biotech Limited (維亞生物科技有限公司), a limited company incorporated in Hong Kong and a direct wholly-owned subsidiary of the Company
“Viva Investment”	Viva Biotech Investment Management Limited, a limited company incorporated in the British Virgin Islands and an indirect wholly-owned subsidiary of the Company
“VIVA Shanghai”	Viva Biotech (Shanghai) Ltd. (維亞生物科技(上海)有限公司), a limited liability company established in the PRC and an indirect wholly-owned subsidiary of the Company

“Viva Sichuan”

Sichuan Viva Benyuan Biotech Limited (四川維亞本苑生物科技股份有限公司), a limited liability company established in the PRC and an indirect wholly-owned subsidiary of the Company

“%”

percentage

By Order of the Board  
**VIVA BIOTECH HOLDINGS**  
**MAO Chen Cheney**  
*Chairman and Chief Executive Officer*

Hong Kong, June 11, 2023

*As of the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*